Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Center for Clinical Research and Prevention | NETWORK |
Not provided
Not provided
Not provided
Not provided
The objectives of this study are: Firstly, to investigate the association between psychiatric disorders and functional somatic disorder (FSD). Secondly, to investigate whether psychiatric disorders are risk factors for newly developed (incident) FSD after a 5-year follow-up period.
Functional somatic disorder (FSD) is a common condition characterized by a persistent pattern of impairing physical symptoms. Our knowledge about what causes the development and perpetuating of these disorders is still sparse, however, it is well accepted that they have a multifactorial aetiology, comprising both biological, psychological, and social factors.
The relationship between FSD and other conditions have been investigated in different manners: A study in patients with severe FSD have shown an increased number of other physical diagnoses compared to healthy controls. A general population-based study has shown FSD to be associated with other self-reported physical diseases, depression, and anxiety. Further, psychopathology has shown to predict irritable bowel syndrome and fibromyalgia, while irritable bowel syndrome has shown to predict common mental disorders (5). However, for some diagnoses, e.g. whiplash associated disorders, the relationship with psychiatric disorders is more inconsistent.
The previous research may carry some limitations: Clinical studies into highly selected patient samples may carry risk of selection bias, and most population-based studies have used self-report for establishing FSD diagnoses and psychiatric diagnoses which may bring risk of misclassification. Hence, more studies with a sound methodology into these aspects are needed.
The proposed longitudinal study includes data from two investigations of the same cohort from the general Danish population. Both validated symptom questionnaires and diagnostic interviews will be used for the establishment of FSD diagnoses and psychiatric discharge diagnoses and prescription medication will be obtained from the comprehensive Danish Central Registries.
Objective
The objective of this study is twofold:
Hypotheses:
Data from the DanFunD (Danish Study of Functional Disorders) baseline and 5-year follow-up investigations will be included. The baseline cohort is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, aged 18 to 76 years. The baseline cohort constitutes data from self-reported validated symptom questionnaires and diagnostic interviews. The follow-up cohort consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort also constitutes data from self-reported validated symptom questionnaires and diagnostic interviews.
Psychiatric diagnoses will be obtained from the Danish National Patient Registry according to the International Classification of Diseases, 10th Revision (ICD-10). In order to obtain cases with more 'mild' psychiatric disorders that do not require hospital admission, prescriptions for relevant pharmacological treatment of these disorders will be obtained from the Danish National Prescription Registry.
Primary outcome (dependent variables):
Participants with FSD will be defined as follows:
Primary explanatory/independent variables:
Psychiatric disorders will be identified by means of
The time frame will be 10 years before the DanFunD baseline investigation and the 5-year period between the baseline and follow-up investigation.
All analyses will be performed using STATA version 17.0. Descriptive tables will be performed with number and percentages of individuals with psychiatric diagnoses (overall psychiatric diagnosis and specific categories: anxiety disorder, depression, bipolar disorder, personality disorder, and stress-related disorder) and use of prescription medication across FSD diagnoses and controls.
Hypothesis 1:
Relevant regression models with FSD obtained at baseline as primary outcome (baseline FSD positive = 1, baseline FSD negative = 0) and a dichotomous variable constituting overall psychiatric diagnoses and/or prescription medicine (at least one: yes = 1, no = 0) received within a period of 10 years before baseline as primary explanatory variable will be performed.
Hypothesis 2:
Relevant regression models with FSD obtained at baseline as primary outcome (baseline FSD positive = 1, baseline FSD negative = 0) and a dichotomous variable constituting each specific diagnosis and prescription medication for the specific diagnoses (anxiety disorder, depression, bipolar disorder, personality disorder, and stress-related disorder) (yes = 1, no = 0) received within a period of 10 years before baseline as primary explanatory variable will be performed.
As some of the prescription medication may be prescribed for several of the included diagnoses, a sub analysis will be performed for hypothesis 2, where only the specific diagnoses will constitute the primary outcome variable, i.e. without prescription medication.
For the analyses of hypotheses 1 and 2, prevalence odds ratios (POR) with 95% confidence intervals (CI) will be used as measure of association. A POR > 1 supports the hypotheses. Depending on number of cases, the analyses will be adjusted for as many of the following covariates (prioritized order) as possible without over fitting the data: 1. Sex, 2. age, 3. social status, and 4. severe physical disease (measured with the Charlson comorbidity index).
Hypothesis 3:
Relevant regression models with newly developed FSD at follow-up as primary outcome (follow-up FSD positive = 1, baseline FSD negative = 0) and a dichotomous variable constituting overall psychiatric diagnoses and/or prescription medicine (at least one: yes = 1, no = 0) received within a period of 10 years before baseline as primary explanatory variable will be performed.
Hypothesis 4:
Relevant regression models with newly developed FSD at follow-up as primary outcome (follow-up FSD positive = 1, baseline FSD negative = 0) and a dichotomous variable constituting each specific diagnosis and prescription medication for the specific diagnoses (anxiety disorder, depression, bipolar disorder, personality disorder, and stress-related disorder) (yes = 1, no = 0) received within a period of 10 years before baseline as primary explanatory variable will be performed.
As some of the prescription medication may be prescribed for several of the included diagnoses, a sub analysis will be performed for hypothesis 4, where only the specific diagnoses will constitute the primary outcome variable, i.e. without prescription medication.
For the analyses of hypotheses 3 and 4, odds ratios (OR) with 95% CI will be used as measure of association. An OR > 1 supports the hypotheses.
Depending on number of cases, the analyses will be adjusted for as many of the following covariates (prioritized order) as possible without over fitting of the data: 1. Sex, 2. age, 3. social status, and 4. severe physical disease (measured with the Charlson comorbidity index).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DanFunD baseline | The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590). | ||
| DanFunD 5-years follow-up investigation | The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094). |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Questionnaire-defined Functional somatic disorder at baseline | Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with self-reported questionnaires. | At the DanFunD baseline investigation |
| Interview-based Functional somatic disorder at baseline | Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with diagnostic interviews. | Time Frame: At the DanFunD baseline investigation |
| Questionnaire-defined Functional somatic disorder at 5-year follow-up | Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with self-reported questionnaires. | Time Frame: At the DanFunD 5-year follow-up investigation |
| Interview-based Functional somatic disorder at 5-year follow-up | Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with diagnostic interviews. | Time Frame: At the DanFunD 5-year follow-up investigation |
| Irritable bowel at baseline | Participants fulfilling the diagnostic criteria for irritable bowel will be identified with self-reported questionnaires | Time Frame: At the DanFunD baseline investigation |
| Irritable bowel at 5-year follow-up | Participants fulfilling the diagnostic criteria for irritable bowel will be identified with self-reported questionnaires |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Presence of psychiatric disorders (overall): Yes/no | Defined as having at least one of the following psychiatric diagnoses: Alcohol and drug abuse, anxiety disorders, depression and bipolar disorders, developmental and behavioural disorders, eating disorders, schizophrenia spectrum disorders, and stress-related disorders. | Time frame: Given within 10 years before the DanFunD baseline investigation. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
A total of 25,368 participants were randomly drawn from the adult general Danish population by means of the the Danish Civil Registration system.
The DanFunD baseline cohort comprises a total of 7,493 (29.5% of invited participants) men and women aged 18-76 years, born in Denmark, and living in the Western part of greater Copenhagen.
The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Per Fink, DMSc | Aarhus University Hospital | Study Chair |
Not provided
Restrictions apply to the availability of data according to Danish law, which means that data cannot be made publicly available. A request for collaboration or access to data can be sent to ckff@regionh.dk. An application for data should consist of a short synopsis of the study planned. Please see our website (www. danfund.org) for more information.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D043183 | Irritable Bowel Syndrome |
| D005356 | Fibromyalgia |
| D015673 | Fatigue Syndrome, Chronic |
| D013001 | Somatoform Disorders |
| ID | Term |
|---|---|
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Time Frame: At the DanFunD 5-year follow-up investigation |
| Chronic widespread pain at baseline | Participants fulfilling the diagnostic criteria for chronic widespread pain will be identified with self-reported questionnaires | Time Frame: At the DanFunD baseline investigation |
| Chronic widespread pain at 5-year follow-up | Participants fulfilling the diagnostic criteria for chronic widespread pain will be identified with self-reported questionnaires. | Time Frame: At the DanFunD 5-year follow-up investigation |
| Chronic fatigue at baseline | Participants fulfilling the diagnostic criteria for chronic fatigue will be identified with self-reported questionnaires. | Time Frame: At the DanFunD baseline investigation |
| Chronic fatigue at 5-year follow-up | Participants fulfilling the diagnostic criteria for chronic fatigue will be identified with self-reported questionnaires. | Time Frame: At the DanFunD 5-year follow-up investigation |
| Presence of anxiety disorders: Yes/no | Defined as having at least one of the ICD-10 codes F40, F41, and F42 or ATC-codes N06A. | Time frame: Given within 10 years before the DanFunD baseline investigation. |
| Presence of depression: Yes/no | Defined as having at least one of the ICD-10 codes F32 and F33 or ATC-codes N06A and N05AN01. | Time frame: Given within 10 years before the DanFunD baseline investigation. |
| Presence of bipolar disorder: Yes/no | Defined as having at least one of the ICD-10 codes F30 and F31 or ATC-codes N06A and N05AN01. | Time frame: Given within 10 years before the DanFunD baseline investigation. |
| Presence of personality disorder: Yes/no | Defined with the ICD-10 code F6. | Time frame: Given within 10 years before the DanFunD baseline investigation. |
| Presence of stress-related disorders: Yes/no | Defined with the ICD-10 code F43. | Time frame: Given within 10 years before the DanFunD baseline investigation. |
| D004066 | Digestive System Diseases |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D004679 | Encephalomyelitis |
| D000090862 | Neuroinflammatory Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001523 | Mental Disorders |